Artículos de revistas sobre el tema "APR-246"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "APR-246".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Jonsson-Videsater, Kerstin, Dina Ali, Hareth Nahi, Sofia Bengtzen, Stefan Deneberg, Christer Paul y Soren Lehmann. "In Vitro and Ex Vivo Studies On Cell Lines and Primary Human Leukemia Cells of the Effects of APR-246 Alone and in Combination with Conventional Chemotherapeutic Drugs." Blood 114, n.º 22 (20 de noviembre de 2009): 2751. http://dx.doi.org/10.1182/blood.v114.22.2751.2751.
Texto completoCeder, Anna Sophia, Sofi E. Eriksson, Emarndeena Haji Cheteh, Vladimir J. N. Bykov, Lars Abrahmsen y Klas G. Wiman. "Impact of combined MRP1 inhibition and mutant p53-targeting compound APR-246." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): e14712-e14712. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14712.
Texto completoMüller, Michael, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David T. W. Jones et al. "Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma". Cancers 13, n.º 17 (5 de septiembre de 2021): 4476. http://dx.doi.org/10.3390/cancers13174476.
Texto completoHong, Yuheng, Tianyuan Ren, Xiaoxuan Wang, Kai Fu, Xianhuo Wang y Huilai Zhang. "APR-246 Reveals a Therapeutic Potential Via Triggering Different Cell Death Mechanisms in Diffuse Large B Cell Lymphoma". Blood 138, Supplement 1 (5 de noviembre de 2021): 3521. http://dx.doi.org/10.1182/blood-2021-150582.
Texto completoSynnott, Naoise C., Alyson M. Murray, Norma O'Donovan, Michael J. Duffy y John Crown. "Combined treatment using the anti-p53 drug, APR-246 and eribulin: Synergistic growth inhibition in p53-mutated breast cancer cells." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e14098-e14098. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14098.
Texto completoXin, Qian, Qinghong Ji, Ying Zhang, Weihong Ma, Baoqing Tian, Yanli Liu, Yunsong Chen et al. "Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer". Oxidative Medicine and Cellular Longevity 2022 (20 de junio de 2022): 1–17. http://dx.doi.org/10.1155/2022/1112987.
Texto completoMohell, Nina, Charlotta Liljebris, Jessica Alfredsson, Ylva Lindman, Maria Uustalu, Thomas Uhlin, Mats R. H. Linderholm y Klas G. Wiman. "Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer". Blood 116, n.º 21 (19 de noviembre de 2010): 1806. http://dx.doi.org/10.1182/blood.v116.21.1806.1806.
Texto completoVenkatesh, Divya, Judith Michels, Cailian Liu, Sadna Budhu, Mariam M. George, Lars Abrahmsen, Roberta Zappasodi, Jedd D. Wolchok y Taha Merghoub. "Abstract 1291: APR-246 enhances tumor immunogenicity even in the absence of p53". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1291. http://dx.doi.org/10.1158/1538-7445.am2022-1291.
Texto completoNagourney, Adam J., Joshua B. Gipoor, Steven S. Evans, Paulo D’Amora, Max S. Duesberg, Paula J. Bernard, Federico Francisco y Robert A. Nagourney. "Therapeutic Targeting of P53: A Comparative Analysis of APR-246 and COTI-2 in Human Tumor Primary Culture 3-D Explants". Genes 14, n.º 3 (19 de marzo de 2023): 747. http://dx.doi.org/10.3390/genes14030747.
Texto completoMacha, Shawn J., Balakrishna Koneru, Trevor Burrow, Charles Zhu, Dzmitry Savitski, Jonas Nance, Kristyn McCoy, Cody Eslinger y C. Patrick Reynolds. "Abstract 6228: APR-246, which restores p53 function, is highly active against alternative lengthening of telomere (ALT) cell lines and PDXs". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 6228. http://dx.doi.org/10.1158/1538-7445.am2022-6228.
Texto completoLiang, Yayun, Rolf A. Brekken y Salman M. Hyder. "Inhibiting Growth of Human Triple-Negative Breast Cancer Cells by Activating Mutant p53 Protein Alone or in Combination With a Phosphatidylserine-Targeting Antibody". Journal of the Endocrine Society 5, Supplement_1 (1 de mayo de 2021): A1022—A1023. http://dx.doi.org/10.1210/jendso/bvab048.2093.
Texto completoMohell, Nina, Charlotta Liljebris, Jessica Alfredsson, Ylva Lindman, Maria Uustalu, Klas G. Wiman y Thomas Uhlin. "Further Preclinical Studies with APR-246, a Novel Anticancer Compound Currently in Clinical Trials for Hematological Malignancies and Prostate Cancer." Blood 114, n.º 22 (20 de noviembre de 2009): 3773. http://dx.doi.org/10.1182/blood.v114.22.3773.3773.
Texto completoDe Sousa, Carla. "Errata ao artigo “Impacto do Confinamento em Crianças e Adolescentes”, Publicado em Acta Med Port 2021 Apr;34(4):245-246." Acta Médica Portuguesa 34, n.º 5 (2 de mayo de 2021): 406. http://dx.doi.org/10.20344/amp.16383.
Texto completoBarutello, Giuseppina, Antonino Di Lorenzo, Alessandro Gasparetto, Chiara Galiazzi, Elisabetta Bolli, Laura Conti y Federica Cavallo. "Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models". Biomedicines 10, n.º 11 (8 de noviembre de 2022): 2843. http://dx.doi.org/10.3390/biomedicines10112843.
Texto completoDemir, Salih, Galina Selivanova, Eugen Tausch, Lisa Wiesmüller, Stephan Stilgenbauer, Geertruy Te Kronnie, Klaus-Michael Debatin y Lüder Hinrich Meyer. "Targeting Mutant p53 in Pediatric Acute Lymphoblastic Leukemia". Blood 126, n.º 23 (3 de diciembre de 2015): 903. http://dx.doi.org/10.1182/blood.v126.23.903.903.
Texto completoMakhale, Ashwini, Devathri Nanayakkara, Prahlad Raninga, Kum Kum Khanna y Murugan Kalimutho. "CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer". International Journal of Molecular Sciences 22, n.º 11 (28 de mayo de 2021): 5782. http://dx.doi.org/10.3390/ijms22115782.
Texto completoAbrams, Stephen L., Przemysław Duda, Shaw M. Akula, Linda S. Steelman, Matilde L. Follo, Lucio Cocco, Stefano Ratti et al. "Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53". Cells 11, n.º 5 (24 de febrero de 2022): 794. http://dx.doi.org/10.3390/cells11050794.
Texto completoDeben, Christophe, Vanessa Deschoolmeester, Jorrit De Waele, Julie Jacobs, Jolien Van den Bossche, An Wouters, Marc Peeters et al. "Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress". Cancers 10, n.º 4 (21 de abril de 2018): 126. http://dx.doi.org/10.3390/cancers10040126.
Texto completoThompson, Meghan C., Matthew S. Davids, Nitin Jain, Jacob D. Soumerai, Praveen Ramakrishnan Geethakumari, Amy Gubits, Denice Hickman et al. "Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)". Blood 136, Supplement 1 (5 de noviembre de 2020): 15–16. http://dx.doi.org/10.1182/blood-2020-139022.
Texto completoGhosh, Arnab, Judith Michel, Divya Venkatesh, Riccardo Mezzadra, Lauren Dong, Fadi Samaan, Ricardo Gomez et al. "Abstract 250: Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 250. http://dx.doi.org/10.1158/1538-7445.am2022-250.
Texto completoLehmann, Sören, Vladimir J. N. Bykov, Dina Ali, Ove Andrén, Honar Cherif, Ulf Tidefelt, Bertil Uggla et al. "Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer". Journal of Clinical Oncology 30, n.º 29 (10 de octubre de 2012): 3633–39. http://dx.doi.org/10.1200/jco.2011.40.7783.
Texto completoNikolaev, Anatoly, John B. Fiveash y Eddy S. Yang. "Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG". International Journal of Molecular Sciences 21, n.º 2 (13 de enero de 2020): 490. http://dx.doi.org/10.3390/ijms21020490.
Texto completoSallman, David A., Amy E. DeZern, Guillermo Garcia-Manero, David P. Steensma, Gail J. Roboz, Mikkael A. Sekeres, Thomas Cluzeau et al. "Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes". Journal of Clinical Oncology 39, n.º 14 (10 de mayo de 2021): 1584–94. http://dx.doi.org/10.1200/jco.20.02341.
Texto completoByskata, Karin, Monika Lukoseviciute, Filippo Tuti, Mark Zupancic, Ourania N. Kostopoulou, Stefan Holzhauser y Tina Dalianis. "Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited". Cancers 15, n.º 1 (23 de diciembre de 2022): 93. http://dx.doi.org/10.3390/cancers15010093.
Texto completoSallman, David A., Amy E. DeZern, David P. Steensma, Kendra L. Sweet, Thomas Cluzeau, Mikkael A. Sekeres, Guillermo Garcia-Manero et al. "Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)". Blood 132, Supplement 1 (29 de noviembre de 2018): 3091. http://dx.doi.org/10.1182/blood-2018-99-119990.
Texto completoMohell, N., J. Alfredsson, Å. Fransson, M. Uustalu, S. Byström, J. Gullbo, A. Hallberg, V. J. N. Bykov, U. Björklund y K. G. Wiman. "APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells". Cell Death & Disease 6, n.º 6 (junio de 2015): e1794-e1794. http://dx.doi.org/10.1038/cddis.2015.143.
Texto completoLi, Jing, Cheng Li, Guoliang Wang, Zhen Liu, Pei Chen, Qichen Yang, Nuo Dong, Huping Wu, Zuguo Liu y Wei Li. "APR-246/PRIMA-1MetInhibits and Reverses Squamous Metaplasia in Human Conjunctival Epithelium". Investigative Opthalmology & Visual Science 57, n.º 2 (11 de febrero de 2016): 444. http://dx.doi.org/10.1167/iovs.15-17519.
Texto completoAryee, D. N. T., S. Niedan, J. Ban, R. Schwentner, K. Muehlbacher, M. Kauer, R. Kofler y H. Kovar. "Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma". British Journal of Cancer 109, n.º 10 (15 de octubre de 2013): 2696–704. http://dx.doi.org/10.1038/bjc.2013.635.
Texto completoKrayem, Mohammad, Fabrice Journe, Murielle Wiedig, Renato Morandini, Ahmad Najem, François Salès, Leon C. van Kempen et al. "p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib". European Journal of Cancer 55 (marzo de 2016): 98–110. http://dx.doi.org/10.1016/j.ejca.2015.12.002.
Texto completoSynnott, Naoise C., Patricia M. McGowan, Aisling Pierce, Maeve Kiely, Norma O'Donovan, John Crown, Patrick A. Kiely y Michael J. Duffy. "PRIMA-1MET (APR-246): A novel targeted therapy for triple negative breast cancer?" Journal of Clinical Oncology 33, n.º 15_suppl (20 de mayo de 2015): e12072-e12072. http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e12072.
Texto completoLiljebris, C., N. Mohell, E. Olaisson, T. Uhlin, K. G. Wiman y S. Lehmann. "APR-246, a new class anticancer compound in phase l/lla clinical trials." Journal of Clinical Oncology 28, n.º 15_suppl (20 de mayo de 2010): TPS183. http://dx.doi.org/10.1200/jco.2010.28.15_suppl.tps183.
Texto completoMagri, Jolanda, Alessandro Gasparetto, Laura Conti, Enzo Calautti, Chiara Cossu, Roberto Ruiu, Giuseppina Barutello y Federica Cavallo. "Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies". Cells 10, n.º 1 (8 de enero de 2021): 108. http://dx.doi.org/10.3390/cells10010108.
Texto completoMagri, Jolanda, Alessandro Gasparetto, Laura Conti, Enzo Calautti, Chiara Cossu, Roberto Ruiu, Giuseppina Barutello y Federica Cavallo. "Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies". Cells 10, n.º 1 (8 de enero de 2021): 108. http://dx.doi.org/10.3390/cells10010108.
Texto completoRökaeus, N., J. Shen, I. Eckhardt, V. J. N. Bykov, K. G. Wiman y M. T. Wilhelm. "PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73". Oncogene 29, n.º 49 (6 de septiembre de 2010): 6442–51. http://dx.doi.org/10.1038/onc.2010.382.
Texto completoDeneberg, S., H. Cherif, V. Lazarevic, P.-O. Andersson, M. von Euler, G. Juliusson y S. Lehmann. "An open-label phase I dose-finding study of APR-246 in hematological malignancies". Blood Cancer Journal 6, n.º 7 (julio de 2016): e447-e447. http://dx.doi.org/10.1038/bcj.2016.60.
Texto completoCluzeau, Thomas, Marie Sebert, Ramy Rahmé, Stefania Cuzzubbo, Anouk Walter-petrich, Jacqueline Lehmann che, Pierre Peterlin et al. "APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)". Blood 134, Supplement_1 (13 de noviembre de 2019): 677. http://dx.doi.org/10.1182/blood-2019-125579.
Texto completoNagourney, Adam Jeremiah, Steven Scott Evans, Max Serge Duesberg, Paulo D'Amora, Paula J. Bernard, Eric Francisco y Robert Alan Nagourney. "Drugging the undruggable-targeting P53: A comparative analysis of APR-246 and coti-2 in human tumor primary culture explants." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e15092-e15092. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e15092.
Texto completoNagourney, Adam Jeremiah, Steven Scott Evans, Max Serge Duesberg, Paulo D'Amora, Paula J. Bernard, Eric Francisco y Robert Alan Nagourney. "Drugging the undruggable-targeting P53: A comparative analysis of APR-246 and coti-2 in human tumor primary culture explants." Journal of Clinical Oncology 40, n.º 16_suppl (1 de junio de 2022): e15092-e15092. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e15092.
Texto completoFang, Y. y C. K. Chang. "PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME". HemaSphere 6 (junio de 2022): 1792–93. http://dx.doi.org/10.1097/01.hs9.0000850504.79008.eb.
Texto completoHang, Wei, Zhi-Xian Yin, Gang Liu, Qinghua Zeng, Xiang-Feng Shen, Qian-Hui Sun, Dong-Dong Li et al. "Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1". Oncogene 37, n.º 25 (18 de enero de 2018): 3384–98. http://dx.doi.org/10.1038/s41388-017-0110-2.
Texto completoSynnott, Naoise C., Stephen F. Madden, Vladimir J. N. Bykov, John Crown, Klas G. Wiman y Michael J. Duffy. "The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells". Translational Oncology 11, n.º 6 (diciembre de 2018): 1343–49. http://dx.doi.org/10.1016/j.tranon.2018.08.009.
Texto completoLiu, David S. H., Matthew Read, Carleen Cullinane, Walid J. Azar, Christina M. Fennell, Karen G. Montgomery, Sue Haupt et al. "APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma". Gut 64, n.º 10 (17 de julio de 2015): 1506–16. http://dx.doi.org/10.1136/gutjnl-2015-309770.
Texto completoRoszkowska, Katarzyna A., Aleksandra Piecuch, Maria Sady, Zdzisław Gajewski y Sylwia Flis. "Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches". International Journal of Molecular Sciences 23, n.º 21 (31 de octubre de 2022): 13287. http://dx.doi.org/10.3390/ijms232113287.
Texto completoPeng, X., M.-Q.-Z. Zhang, F. Conserva, G. Hosny, G. Selivanova, V. J. N. Bykov, E. S. J. Arnér y K. G. Wiman. "APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase". Cell Death & Disease 4, n.º 10 (octubre de 2013): e881-e881. http://dx.doi.org/10.1038/cddis.2013.417.
Texto completoAli, Dina, Kerstin Jönsson-Videsäter, Stefan Deneberg, Sofia Bengtzén, Hareth Nahi, Christer Paul y Sören Lehmann. "APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells". European Journal of Haematology 86, n.º 3 (11 de enero de 2011): 206–15. http://dx.doi.org/10.1111/j.1600-0609.2010.01557.x.
Texto completoSaha, Manujendra N., Hua Jiang, Yijun Yang, Donna Reece y Hong Chang. "PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa". Molecular Cancer Therapeutics 12, n.º 11 (12 de septiembre de 2013): 2331–41. http://dx.doi.org/10.1158/1535-7163.mct-12-1166.
Texto completoLi, Xiao-Lan, Jianbiao Zhou, Zit-Liang Chan, Jing-Yuan Chooi, Zhi-Rong Chen y Wee-Joo Chng. "PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms". Oncotarget 6, n.º 34 (1 de octubre de 2015): 36689–99. http://dx.doi.org/10.18632/oncotarget.5385.
Texto completoLyle, MS, PA-C, Lindsey. "ASH Highlights and Commentary: Myeloid Malignancies". Journal of the Advanced Practitioner in Oncology 13, n.º 2 (1 de marzo de 2022): 15–23. http://dx.doi.org/10.6004/jadpro.2022.13.2.11.
Texto completoSeipel, Katja, Basil Kopp, Ulrike Bacher y Thomas Pabst. "BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia". Cancers 13, n.º 3 (2 de febrero de 2021): 581. http://dx.doi.org/10.3390/cancers13030581.
Texto completoDe La Rosa, Javier, Alejandro Urdiciain, María Zelaya, Idoya Zazpe, Bárbara Meléndez, Juan Rey, Miguel Idoate et al. "APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells". International Journal of Oncology 58, n.º 3 (26 de enero de 2021): 312–30. http://dx.doi.org/10.3892/ijo.2021.5177.
Texto completo